ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3044

Endothelin 1 Induces a Myofibroblastic Phenotype in Vascular Smooth Muscle Cells. A Mechanism Potentially Contributing to Vascular Remodeling and Intimal Hyperplasia in Giant Cell Arteritis

Ester Planas-Rigol1, Nekane Terrades-Garcia2, Marc Corbera-Bellalta2, Ester Lozano2, Marco Antonio Alba2, Georgina Espígol-Frigolé3, Sergio Prieto-González2, Marta Segarra2, Jose Hernández-Rodríguez2, Sara Preciado4, Rodolfo Lavilla4 and Maria C. Cid2, 1Vasculitis research unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 2Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 3Vasculitis Research Unit, Systemic Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 4Laboratory of Organic Chemistry, Faculty of Pharmacy. Barcelona Science Park, Barcelona, Spain

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Cell Migration, giant cell arteritis, Inflammation, intima medial thickness and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Vasculitis III: Pathogenic Mechanisms

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Giant cell arteritis (GCA) is a vascular inflammatory disease involving large and medium sized arteries, particularly the cranial vessels. Inflammation-induced vascular remodeling leads to vascular occlusion and ischemic symptoms and complications including partial or complete visual loss and, in some cases, stroke or other symptoms of vascular insufficiency. Pathogenic mechanisms contributing to this process are incompletely understood although vascular smooth muscle cell (VSMC) acquisition of a myofibroblastic phenotype might be involved. Over-expression of endothelin-1 (ET-1) and its receptors ETAR and ETBR in GCA lesions as well as increased serum concentrations of ET-1 in patients with ischemic complications has been previously reported (Lozano E et al Ann Rheum Dis 2010). The most investigated function of ET-1 in VSMC is vascular tone regulation. In recent years, it has been shown that ET-1 may contribute to myofibroblast differentiation of fibroblasts, a crucial step in lung and skin fibrogenic diseases. Whether ET-1 has similar effects on VSMC contributing to vascular occlusion has not been investigated. The aim of this study is to investigate if ET-1 induces a migratory myofibroblastic phenotype in human temporal artery (TA) -derived VSMC which might contribute to vascular remodeling and ischemic complications.

Methods: Ex vivo culture of TAs into three-dimensional matrix, migration assays using primary cultures of TA-derived VSMC, co-culture of TA-derived VSMC with peripheral blood mononuclear cells. Immunofluorescence and confocal microscopy of TA, qRT-PCR, immunoassay and western-blot.

Results: In GCA lesions ET-1 was mainly produced by inflammatory cells whereas VSMC overexpressed ET-1 receptors which enhanced their ability to respond to ET-1. ET-1 promoted a spread morphology in cultured VSMC and stimulated their migration by inducing focal adhesion kinase (FAK) phosphorylation at Y397 permitting the association with p85 subunit of PI3Kinase which co-localized with FAK at the cell protrusions of migrating cells. Accordingly, inhibition of both FAK and PI3K abrogated ET-1 induced migration. Interestingly, ET-1 treatment of cultured non pathological TAs promoted the disorganization of the artery layers as a consequence of VSMC migration towards the intima layer. Consistently, blockade of ETAR and ETBR with BQ123 and BQ788 antagonists inhibited ET-1 induced VSMC migration and VSMC outgrowth from cultured GCA-arteries as well as reduced Y397FAK phosphorylation in vitro and ex vivo.

Conclusion: ET-1 may be involved in GCA vascular occlusion by promoting VSMC migration towards the intimal layer, a mechanism involving either ETAR or ETBR. Suported by SAF 2014/57708-R, PIE 13/00033 and FEDER.


Disclosure: E. Planas-Rigol, None; N. Terrades-Garcia, None; M. Corbera-Bellalta, None; E. Lozano, None; M. A. Alba, None; G. Espígol-Frigolé, None; S. Prieto-González, None; M. Segarra, None; J. Hernández-Rodríguez, None; S. Preciado, None; R. Lavilla, None; M. C. Cid, None.

To cite this abstract in AMA style:

Planas-Rigol E, Terrades-Garcia N, Corbera-Bellalta M, Lozano E, Alba MA, Espígol-Frigolé G, Prieto-González S, Segarra M, Hernández-Rodríguez J, Preciado S, Lavilla R, Cid MC. Endothelin 1 Induces a Myofibroblastic Phenotype in Vascular Smooth Muscle Cells. A Mechanism Potentially Contributing to Vascular Remodeling and Intimal Hyperplasia in Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/endothelin-1-induces-a-myofibroblastic-phenotype-in-vascular-smooth-muscle-cells-a-mechanism-potentially-contributing-to-vascular-remodeling-and-intimal-hyperplasia-in-giant-cell-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/endothelin-1-induces-a-myofibroblastic-phenotype-in-vascular-smooth-muscle-cells-a-mechanism-potentially-contributing-to-vascular-remodeling-and-intimal-hyperplasia-in-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology